Subscribe To
EPIX / ESSA Pharma: One Asset, One Program Company With Little Data
EPIX News
By Seeking Alpha
February 6, 2023
ESSA Pharma: One Asset, One Program Company With Little Data
EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of more_horizontal
By Seeking Alpha
November 15, 2022
ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer
The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cance more_horizontal